In 2 clinical studies, a total of 335 participants with tardive dyskinesia (TD) were studied for 12 weeks.1

  • A total of 220 participants took AUSTEDO® and a total of 115 participants took placebo (inactive tablets).

Primary goal

The primary goal of both studies was to identify the change in involuntary movements—as measured by the Abnormal Involuntary Movement Scale (AIMS) total score—from the beginning to the end of the 12-week studies. The AIMS total score was used to measure the uncontrolled movements of TD.1

Understanding the AIMS score

The AIMS test uses a checklist to assess the severity of involuntary movements and can also be used to track changes in the movements over time. The test rates movements over multiple areas of the body, scoring severity of involuntary movements in each area from 0-4, with 0 = no movements and 4 = severe movements.1,2

Image depicting areas of the body used to calculate the Abnormal Involuntary Movement Scale (AIMS) total score.

Download the Doctor Discussion Guide

This resource can help you and your doctor decide if AUSTEDO® is right for you.

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) current Prescribing Information. Teva Pharmaceuticals USA, Inc. 2. Abnormal Involuntary Movements Scale (AIMS) - overview. Center for Quality Assessment and Improvement in Mental Health website. http://www.cqaimh.org/pdf/tool_aims.pdf. Accessed September 4, 2019.